Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Joaquin Garcia-Solorio, Juan Carlos Núñez-Enriquez, Marco Jiménez-Olivares, Janet Flores-Lujano, Fernanda Flores-Espino, Carolina Molina-Garay, Alejandra Cervera, Diana Casique-Aguirre, José Gabriel Peñaloza-Gonzalez, Ma Del Rocío Baños-Lara, Ángel García-Soto, César Alejandro Galván-Díaz, Alberto Olaya-Vargas, Hilario Flores Aguilar, Minerva Mata-Rocha, Miguel Ángel Garrido-Hernández, Juan Carlos Solís-Poblano, Nuria Citlalli Luna-Silva, Lena Sarahi Cano-Cuapio, Pierre Mitchel Aristil-Chery, Fernando Herrera-Quezada, Karol Carrillo-Sanchez, Anallely Muñoz-Rivas, Luis Leonardo Flores-Lagunes, Elvia Cristina Mendoza-Caamal, Beatriz Eugenia Villegas-Torres, Vincent González-Osnaya, Elva Jiménez-Hernández, José Refugio Torres-Nava, Jorge Alfonso Martín-Trejo, María de Lourdes Gutiérrez-Rivera, Rosa Martha Espinosa-Elizondo, Laura Elizabeth Merino-Pasaye, María Luisa Pérez-Saldívar, Silvia Jiménez-Morales, Everardo Curiel-Quesada, Haydeé Rosas-Vargas, Juan Manuel Mejía-Arangure, Carmen Alaez-Verson
BACKGROUND: Recurrent genetic alterations contributing to leukemogenesis have been identified in pediatric B-cell Acute Lymphoblastic Leukemia (B-ALL), and some are useful for refining classification, prognosis, and treatment selection. IKZF1plus is a complex biomarker associated with a poor prognosis. It is characterized by IKZF1 deletion coexisting with PAX5 , CDKN2A/2B , or PAR1 region deletions. The mutational spectrum and clinical impact of these alterations have scarcely been explored in Mexican pediatric patients with B-ALL...
2024: Frontiers in Oncology
#2
JOURNAL ARTICLE
D Wang, C Zhao, X J Xu
No abstract text is available yet for this article.
April 16, 2024: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
#3
REVIEW
Tommaso Silvano Aronica, Miriam Carella, Carmela Rita Balistreri
Changes in the components, variety, metabolism, and products of microbiomes, particularly of the gut microbiome (GM), have been revealed to be closely associated with the onset and progression of numerous human illnesses, including hematological neoplasms. Among the latter pathologies, there is acute lymphoblastic leukemia (ALL), the most widespread malignant neoplasm in pediatric subjects. Accordingly, ALL cases present a typical dysfunctional GM during all its clinical stages and resulting inflammation, which contributes to its progression, altered response to therapy, and possible relapses...
March 31, 2024: International Journal of Molecular Sciences
#4
JOURNAL ARTICLE
Husam B R Alabed, Roberto Maria Pellegrino, Sandra Buratta, Anair Graciela Lema Fernandez, Roberta La Starza, Lorena Urbanelli, Cristina Mecucci, Carla Emiliani, Paolo Gorello
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive tumor mainly affecting children and adolescents. It is driven by multiple genetic mutations that together define the leukemic phenotype. Interestingly, based on genetic alterations and/or deregulated expression, at least six genetic subgroups have been recognized. The TAL/LMO subgroup is one of the most represented genetic subgroups, characterizing 30-45% of pediatric T-ALL cases. The study of lipid and metabolic profiles is increasingly recognized as a valuable tool for comprehending the development and progression of tumors...
March 31, 2024: International Journal of Molecular Sciences
#5
REVIEW
Marika Kulczycka, Kamila Derlatka, Justyna Tasior, Maja Sygacz, Monika Lejman, Joanna Zawitkowska
Infant acute lymphoblastic leukemia (Infant ALL) is a kind of pediatric ALL, diagnosed in children under 1 year of age and accounts for less than 5% of pediatric ALL. In the infant ALL group, two subtypes can be distinguished: KMT2A -rearranged ALL, known as a more difficult to cure form and KMT2A - non-rearranged ALL with better survival outcomes. As infants with ALL have lesser treatment outcomes compared to older children, it is pivotal to provide novel treatment approaches. Progress in the development of molecularly targeted therapies and immunotherapy presents exciting opportunities for potential improvement...
March 27, 2024: International Journal of Molecular Sciences
#6
JOURNAL ARTICLE
Maria T Papadopoulou, Paraskevi Panagopoulou, Efstathia Paramera, Alexandros Pechlivanis, Christina Virgiliou, Eugenia Papakonstantinou, Maria Palabougiouki, Maria Ioannidou, Eleni Vasileiou, Athanasios Tragiannidis, Evangelos Papakonstantinou, Georgios Theodoridis, Emmanuel Hatzipantelis, Athanasios Evangeliou
INTRODUCTION: Acute lymphoblastic leukemia (ALL) is the most prevalent childhood malignancy. Despite high cure rates, several questions remain regarding predisposition, response to treatment, and prognosis of the disease. The role of intermediary metabolism in the individualized mechanistic pathways of the disease is unclear. We have hypothesized that children with any (sub)type of ALL have a distinct metabolomic fingerprint at diagnosis when compared: (i) to a control group; (ii) to children with a different (sub)type of ALL; (iii) to the end of the induction treatment...
March 24, 2024: Diagnostics
#7
JOURNAL ARTICLE
Hisham S Abou-Auda, Fatimah Alotaibi, Sary Alsanea, Abdulrahman Alwhaibi, Mohammed M Almutairi, Ziyad Alrabiah, Abdullah Alsultan, Majed Al Jeraisy
Understanding the pharmacokinetics of gentamicin is essential in special populations, such as pediatric patients with acute lymphoblastic leukemia (ALL), in light of previous studies indicating that ALL patients have a lower volume of distribution than non-ALL patients. Furthermore, validation of such results is needed to ensure their clinical application. Accordingly, this single-center, retrospective, cross-sectional study compares the pharmacokinetic parameters of volume of distribution and clearance (Cl) of gentamicin between ALL and non-ALL patients...
May 2024: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
#8
EDITORIAL
Lindsey Murphy, Ibrahim Aldoss
No abstract text is available yet for this article.
March 27, 2024: Translational Pediatrics
#9
JOURNAL ARTICLE
Kellen Gandy, Timothy R Koscik, Tyler Alexander, Jeffrey D Steinberg, Kevin R Krull, Ellen van der Plas
BACKGROUND: Survivors of pediatric acute lymphoblastic leukemia (ALL) exhibit abnormal neurocognitive outcomes that are possibly due to exposures to neurotoxic chemotherapy agents. This study aimed to determine the feasibility of characterizing long-term neuroanatomical changes with in vivo neuroimaging in a preclinical model of treatment for ALL. METHODS: Female mice (C57BL/6) were randomly assigned to a saline control group (n=10) or a treatment group (n=10) that received intrathecal methotrexate and oral dexamethasone (IT-MTX + DEX)...
March 27, 2024: Translational Pediatrics
#10
REVIEW
Aimee C Talleur, Vanessa A Fabrizio, Richard Aplenc, Stephan A Grupp, Crystal Mackall, Robbie Majzner, Rosa Nguyen, Rayne Rouce, Amy Moskop, Kevin O McNerney
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable efficacy in relapsed/refractory (r/r) B cell malignancies, including in pediatric patients with acute lymphoblastic leukemia (ALL). Expanding this success to other hematologic and solid malignancies is an area of active research and, although challenges remain, novel solutions have led to significant progress over the past decade. Ongoing clinical trials for CAR T cell therapy for T cell malignancies and acute myeloid leukemia (AML) have highlighted challenges, including antigen specificity with off-tumor toxicity and persistence concerns...
April 6, 2024: Transplantation and cellular therapy
#11
JOURNAL ARTICLE
Emma Kroeze, Ingram Iaccarino, Michelle M Kleisman, Mayukh Mondal, Thomas Beder, Mouhamad Khouja, Marc P Höppner, Marijn A Scheijde-Vermeulen, Lennart A Kester, Monika Brüggemann, Claudia D Baldus, Gunnar Cario, Reno S Bladergroen, Nathalie Garnier, Andishe Attarbaschi, Jaime Verdu-Amorós, Rosemary Sutton, Elizabeth A Macintyre, Kenneth Scholten, Laura Arias Padilla, Birgit Burkhardt, Auke Beishuizen, Monique L den Boer, Roland P Kuiper, Jan L C Loeffen, Judith M Boer, Wolfram Klapper
Pediatric B-cell precursor (BCP) lymphoblastic malignancies are neoplasms with manifestation either in bone marrow/blood (BCP acute lymphoblastic leukemia, BCP-ALL) or less common in extramedullary tissue (BCP lymphoblastic lymphoma, BCP-LBL). Although both presentations are similar in morphology and immunophenotype, molecular studies are virtually restricted to BCP-ALL so far. The lack of molecular studies on BCP-LBL is due to its rarity and the restriction to small, mostly formalin-fixed paraffin embedded (FFPE) tissues...
April 8, 2024: Blood
#12
JOURNAL ARTICLE
Meghan Tokala, Jacee Weber, Renee Gilbert, Meredith L Dreyer Gillette, Keith J August, Christie A Befort, Carolyn R Bates
BACKGROUND: Changes in health behaviors and weight are common during the early phases of pediatric acute lymphoblastic leukemia treatment, and may negatively impact treatment tolerability.. Given that ALL is most prevalent in children, caregivers play an essential role in shaping health behaviors during treatment. This study presents a qualitative analysis of semi-structured interviews with caregivers of youth in the early phases of ALL treatment. PROCEDURE: Caregivers (N = 17, 95% female) of a child (M age = 6...
April 7, 2024: Pediatric Blood & Cancer
#13
REVIEW
Zhongbo Hu, Yogindra Persaud, Sanjay Ahuja
Asparaginase is essential in the initial management of acute lymphoblastic leukemia (ALL) but frequently leads to venous thromboembolism (VTE). Using anticoagulants for primary VTE prevention has been studied with no consensus. We conducted a systematic literature search in PubMed, Scopus, and Web of science and performed random-effect meta-analysis using Mantel-Haenszel method in RevMan 5.4 to analyze primary pharmacological thromboprophylaxis during asparaginase treatment in early-phase (induction, consolidation, or intensification phase) therapy in patients with ALL with all ages and followed with subgroup analysis by age...
April 5, 2024: Critical Reviews in Oncology/hematology
#14
JOURNAL ARTICLE
R Pradeep, Sudeshna Rakshit, Geetha Shanmugam, Melvin George, Koustav Sarkar
BACKGROUND: T-ALL is an aggressive hematological tumor that develops as the result of a multi-step oncogenic process which causes expansion of hematopoietic progenitors that are primed for T cell development to undergo malignant transformation and growth. Even though first-line therapy has a significant response rate, 40% of adult patients and 20% of pediatric patients will relapse. Therefore, there is an unmet need for treatment for relapsed/refractory T-ALL to develop potential targeted therapies...
April 4, 2024: Clinical Immunology: the Official Journal of the Clinical Immunology Society
#15
JOURNAL ARTICLE
Chih-Hsiang Yu, Ying-Hui Su, Shiann-Tarng Jou, Meng-Yao Lu, Chien-Yu Lin, Kai-Hsin Lin, Hsiu-Hao Chang, Shu-Wei Chou, Ya-Hui Huang, Dong-Tsamn Lin, Shu-Wha Lin, Hsuan-Yu Chen, Ya-Hsuan Chang, Yung-Li Yang
The lack of expression of terminal deoxynucleotidyl transferase (TdT) is frequently associated with KMT2A-rearranged subtype of pediatric acute lymphoblastic leukemia (ALL). However, this association has not been investigated extensively in the Asian population. A retrospective analysis of TdT expression in pediatric B-cell ALL (B-ALL) was performed in patients treated using the Taiwan Pediatric Oncology Group (TPOG) ALL 2002 and 2013 protocols. Among the 331 patients with B-ALL, 12 patients showed TdT negativity at initial diagnosis...
April 2, 2024: Pathology, Research and Practice
#16
JOURNAL ARTICLE
Shuojie Liu, Bin Hu, Jiaqin Zhang
OBJECTIVE: To assess the epidemiological characteristics and prognostic factors of acute leukemia (AL) in children and adolescents, and make comparisons between pediatric and adult patients. METHODS: This retrospective cohort study enrolled AL patients from the Surveillance, Epidemiology, and End Results (SEER) 1975-2016. OS in children and adolescents and adults with AL was compared and analyzed separately by age and AL subtype. RESULTS: Totally 61,694 AL patients were identified, with 45,411 (73...
December 2024: Hematology (Amsterdam, Netherlands)
#17
JOURNAL ARTICLE
Chi Zhang, Kathy Yuen Yee Chan, Wing Hei Ng, John Tak Kit Cheung, Qiwei Sun, Han Wang, Po Yee Chung, Frankie Wai Tsoi Cheng, Alex Wing Kwan Leung, Xiao-Bing Zhang, Po Yi Lee, Siu Ping Fok, Guanglan Lin, Ellen Ngar Yun Poon, Jian-Hua Feng, Yan-Lai Tang, Xue-Qun Luo, Li-Bin Huang, Wei Kang, Patrick Ming Kuen Tang, Junbin Huang, Chun Chen, Junchao Dong, Ester Mejstrikova, Jiaoyang Cai, Yu Liu, Shuhong Shen, Jun J Yang, Patrick Man Pan Yuen, Chi Kong Li, Kam Tong Leung
Resistance to glucocorticoids (GCs), the common agents for remission induction in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL), poses a significant therapeutic hurdle. Therefore, dissecting the mechanisms shaping GC resistance could lead to new treatment modalities. Here, we showed that CD9- BCP-ALL cells were preferentially resistant to prednisone and dexamethasone over other standard cytotoxic agents. Concordantly, we identified significantly more poor responders to the prednisone prephase among BCP-ALL patients with a CD9- phenotype, especially for those with adverse presenting features including older age, higher white cell count and BCR-ABL1...
April 4, 2024: Haematologica
#18
JOURNAL ARTICLE
Shaojie Shi, Haiyan Xing, Xiangping Xu, Jinquan Chai, Zixuan Lu, Jianyong Wang, Bin Wang
The potential of cytotoxic CD4+ T cells and tissue resident memory T cells (Trm) in achieving adult leukemia remission have been highlighted [1,2]. We hypothesized that CXCR6 could serve as a marker for cytotoxic CD4+ Trm cells in the bone marrow (BM) of pediatric B-ALL patients. Flow cytometry (FCM) and published single cell RNA sequencing (scRNA-seq) datasets were employed to characterize CXCR6+ CD4+ T cells in the BM and peripheral blood (PB) of pediatric B-ALL patients and healthy donors. FCM, scRNA-seq and co-culture were utilized to explore the cytotoxicity of CXCR6+ CD4+ T cells in vitro based on in vitro induction of CXCR6+ CD4+ T cells using tumor antigens and peripheral blood mononuclear cells (PBMCs)...
April 2, 2024: International Immunopharmacology
#19
JOURNAL ARTICLE
Liliana Velasco-Hidalgo, Alejandro González-Garay, Blanca Angélica Segura-Pacheco, Ana Luisa Esparza-Silva, Miguel Enrique Cuéllar Mendoza, Cecilia Ochoa-Drucker, Sofía Campos-Ugalde, Luis Eduardo Bernabé-Gaspar, Marta Zapata-Tarrés
INTRODUCTION: Management of pediatric cancer patients involves invasive procedures such as punctures, injections, catheter placements, and chemotherapy which can generate fatigue, nausea, vomiting, anxiety, and pain. Virtual Reality (VR) is a nonpharmacological intervention classified as a cognitive-behavioral method to relieve symptoms. METHODS: We designed a crossover protocol and included 20 patients between 9 and 12 years old; ten were male. All patients had acute lymphoblastic leukemia diagnosis and were treatedwith St...
2024: Frontiers in Oncology
#20
JOURNAL ARTICLE
Xinyu Li, Shaofen Lin, Ning Liao, Huirong Mai, Xingjiang Long, Lili Liu, Beiyan Wu, Qiwen Chen, Qian Kong, Xianling Kong, Lixia Liu, Jiayue Qin, Jianpei Fang, Dunhua Zhou
The next-generation sequencing technologies application discovers novel genetic alterations frequently in pediatric acute lymphoblastic leukemia (ALL). RAS signaling pathway mutations at the time of relapse ALL frequently appear as small subclones at the time of onset, which are considered as the drivers in ALL relapse. Whether subclones alterations in the RAS signaling pathway should be considered for risk group stratification of ALL treatment is not decided yet. In this work, we investigate the RAS signaling pathway mutation spectrum and the related prognosis in pediatric ALL...
May 2024: Hematological Oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
